Want to see GNLX full AI Analyst Report?
GNLX Stock Chart & Stats
$2.89
$0.03(1.21%)
At close: 4:00 PM EDT
$2.89
$0.03(1.21%)
Day’s Range― - ―
52-Week Range$2.29 - $8.54
Previous CloseN/A
Volume44.18K
Average Volume (3M)156.94K
Market Cap
$131.83M
Enterprise Value$100.43M
Total Cash (Recent Filing)$26.21M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding44,840,416
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue12.55K
Enterprise Value/Gross Profit-353.63
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$23.50Price Target Upside713.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest debt relative to equity provides structural financial flexibility and lowers near-term solvency risk. For a cash-burning biotech this reduces fixed interest obligations and gives management more optionality to fund R&D or seek partnerships before urgent capital raises, supporting program continuity.
Focused Platform And Lead AssetA focused, differentiated platform (oncolytic viral immunotherapies) and a single lead candidate simplify clinical strategy and resource allocation. Specialization in solid tumors including ovarian cancer targets unmet needs where successful clinical outcomes can translate into durable competitive positioning and partnership interest.
Early Improvement In LossesA modest improvement in net loss versus the prior year signals initial progress on cost control or program execution. While still loss-making, this directional improvement can be sustained into future periods through disciplined spend or milestone-driven partnerships, reducing financing pressure over time if continued.
Bears Say
High Cash BurnSustained multi‑tens‑of‑millions annual cash burn is a structural vulnerability. It rapidly consumes available resources, forces recurring capital raises, and can disrupt long‑term program timelines if market conditions tighten, limiting the company's ability to complete trials or scale operations without dilution.
Minimal Revenue And Negative MarginsPractically no operating revenue and persistently negative margins indicate lack of commercial validation. The company remains entirely dependent on external funding and milestone events for value creation, increasing binary outcome risk and making long‑term cash generation uncertain until commercialization.
Financing And Dilution RiskHistorical equity volatility and prior negative equity underscore ongoing financing vulnerability. Given heavy cash burn and weak revenue, the company will likely need additional capital, which tends to dilute existing shareholders and can pressure management to prioritize short‑term financing over optimal strategic choices.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $2.29 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $131.83M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Aug 18, 2026 which is in 12 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,840,416 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (713.15% Upside)
$23.50 (713.15% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $60.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.2%
Last 30 Days ▼ 13.8%
Last 30 Days ▼ 13.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.96%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$23.50
▲(713.15% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
7.20% Insiders
4.67% Mutual Funds
6.21% Other Institutional Investors
77.91% Public Companies and
Individual Investors